Alvogen Taiwan

Alvogen Taiwan 
1F, No.6, Lane 160, Sec 1 
XinSheng South Road 
Taipei, 100 

886 2 23511932
886 2 23511502

Alvogen has an office in Taipei, with four employees. The office is lead by Siegfried Gschliesser, Regional Directory for North Asia. Alvogen’s approach in Taiwan is to register new products on the market, starting with a portfolio of high quality cosmetics in the Women/ Children and Gastro health range, and gradually build up product offering, through partnerships and possible portfolio acquisitions.

The Taiwan pharmaceutical market is very competitive with high volume growth, recent changes in implementing stricter quality standards and a push by the National Health Insurance to reduce cost will lead to many changes in the market.

Some USD 1.6 bn. are currently being generated by the sale of patented Originator products and this market segment is expected to turn generic within the next few years. These changes will open up lots of opportunities for fast moving, decisive companies with large portfolios of high quality products and strong pipelines. "Alvogen Taiwan is very well positioned to capture these opportunities and we are looking forward to a rapid increase in market share and revenue growth", says Siegfried Gschliesser, Regional Director Taiwan.

Market info

The total pharmaceutical market is around $4 billion and is expected to grow by about 5% in 2015. The share of the generic market by volume is around 40%, 4.8% in value terms.

Taiwan is a hospital-based market, with hospitals representing some 78% of the market, followed by retail drugstores and GP/Clinics. The top 10 pharmaceutical companies account for almost 50% of total market value and multinational companies represent some 77% of total market value, according to company estimates and public sources.

  • $4BTotal pharmaceutical
  • 5%Annual pharmaceutical
    market growth by 2015
  • 10%Generics penetration
    in value
  • 40%Generics penetration
    in volume

Life at Alvogen Thailand